Merck (MRK) is reportedly planning to double the production of molnupiravir, an antiviral COVID pill, next year. The Financial Times reported the drugmaker has secured deals to provide COVID ...
Merck said Wednesday it had licensed an experimental GLP-1 obesity pill from a Chinese drugmaker, dampening hopes for the obesity-focused biotechs that had appeared to be likely acquisition ...
The FDA's authorization allows high-risk people ages 12 or older to receive the pills. The agency went on to authorize Merck's antiviral pill on Tuesday for use in high-risk people 18 or older who ...
Hosted on MSN1mon
Merck’s weight-loss pill deal: what it means for Eli LillyMerck & Co Inc (NYSE: MRK) is in focus this morning after announcing a $2.0 billion deal with Hansoh Pharma. The said agreement wins it rights to HS-10535 – an experimental weight-loss pill ...
The Food and Drug Administration announcement on Merck's molnupiravir comes one day after the agency cleared a competing drug from Pfizer. Pfizer's pill, Paxlovid, is likely to become the first ...
Amid the ongoing resurgence of new Covid-19 cases in India, an expert panel of the Central Drugs Standard Control Organisation on Tuesday approved Merck's anti-viral drug molnupiravir for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback